Movement Alert｜Sanofi Rises 3.09% in Pre-Market Trading, First-in-Class Drug Venglustat Granted FDA Priority Review

Market Focus06-04

On June 4, Sanofi rose 3.09% in pre-market trading, trading at $43.68/share, with trading volume of $356,200. The move was driven by the announcement that its first-in-class therapy Venglustat has been accepted by the FDA with Priority Review designation for the treatment of Type III Gaucher Disease (GD3).

The FDA acceptance was primarily based on positive results from the Phase III LEAP2MONO study. If approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3, expanding Sanofi's portfolio for lysosomal storage disease patients. The FDA's target action date is set for November 25. Additionally, Sanofi has advanced a JAK/ROCK dual-target inhibitor into clinical application, further broadening its innovative pipeline in hematology and transplantation, which collectively bolstered market sentiment.

Within the Pharmacy sector where Sanofi belongs, the overall sector showed modest gains. Among individual stocks, Eli Lilly up 1.27%, Johnson & Johnson up 0.97%, Merck up 0.78%, Bristol-Myers Squibb up 0.60%, Pfizer up 0.59%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142049791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142049791","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Sanofi Rises 3.09% in Pre-Market Trading, First-in-Class Drug Venglustat Granted FDA Priority Review","media":"Market Focus","content":"<p><p>On June 4, Sanofi rose 3.09% in pre-market trading, trading at $43.68/share, with trading volume of $356,200. The move was driven by the announcement that its first-in-class therapy Venglustat has been accepted by the FDA with Priority Review designation for the treatment of Type III Gaucher Disease (GD3).</p><p>The FDA acceptance was primarily based on positive results from the Phase III LEAP2MONO study. If approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3, expanding Sanofi's portfolio for lysosomal storage disease patients. The FDA's target action date is set for November 25. Additionally, Sanofi has advanced a JAK/ROCK dual-target inhibitor into clinical application, further broadening its innovative pipeline in hematology and transplantation, which collectively bolstered market sentiment.</p><p>Within the Pharmacy sector where Sanofi belongs, the overall sector showed modest gains. Among individual stocks, Eli Lilly up 1.27%, Johnson & Johnson up 0.97%, Merck up 0.78%, Bristol-Myers Squibb up 0.60%, Pfizer up 0.59%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sanofi Rises 3.09% in Pre-Market Trading, First-in-Class Drug Venglustat Granted FDA Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sanofi Rises 3.09% in Pre-Market Trading, First-in-Class Drug Venglustat Granted FDA Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Sanofi rose 3.09% in pre-market trading, trading at $43.68/share, with trading volume of $356,200. The move was driven by the announcement that its first-in-class therapy Venglustat has been accepted by the FDA with Priority Review designation for the treatment of Type III Gaucher Disease (GD3).</p><p>The FDA acceptance was primarily based on positive results from the Phase III LEAP2MONO study. If approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3, expanding Sanofi's portfolio for lysosomal storage disease patients. The FDA's target action date is set for November 25. Additionally, Sanofi has advanced a JAK/ROCK dual-target inhibitor into clinical application, further broadening its innovative pipeline in hematology and transplantation, which collectively bolstered market sentiment.</p><p>Within the Pharmacy sector where Sanofi belongs, the overall sector showed modest gains. Among individual stocks, Eli Lilly up 1.27%, Johnson & Johnson up 0.97%, Merck up 0.78%, Bristol-Myers Squibb up 0.60%, Pfizer up 0.59%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"","article_id":"1142049791","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142049791","pubTimestamp":1780563974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Sanofi rose 3.09% in pre-market trading, trading at $43.68/share, with trading volume of $356,200. The move was driven by the announcement that its first-in-class therapy Venglustat has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特"},"translate_title":"动静快讯|赛诺菲盘前涨3.09%，同类首创药物Venglustat获FDA优先审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1},"content_text":"On June 4, Sanofi rose 3.09% in pre-market trading, trading at $43.68/share, with trading volume of $356,200. The move was driven by the announcement that its first-in-class therapy Venglustat has been accepted by the FDA with Priority Review designation for the treatment of Type III Gaucher Disease (GD3).The FDA acceptance was primarily based on positive results from the Phase III LEAP2MONO study. If approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3, expanding Sanofi's portfolio for lysosomal storage disease patients. The FDA's target action date is set for November 25. Additionally, Sanofi has advanced a JAK/ROCK dual-target inhibitor into clinical application, further broadening its innovative pipeline in hematology and transplantation, which collectively bolstered market sentiment.Within the Pharmacy sector where Sanofi belongs, the overall sector showed modest gains. Among individual stocks, Eli Lilly up 1.27%, Johnson & Johnson up 0.97%, Merck up 0.78%, Bristol-Myers Squibb up 0.60%, Pfizer up 0.59%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142049791","isCrawlerRequest":true}